Parcopa vs TR-012001
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Parcopa
Rights held by UCB; US product discontinued
NCT00139867 · Phase 3 · completed
The study used randomization and a conventional carbidopa/levodopa comparator, but it was open-label and focused on treatment preference rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Onset of action: time to a 30% decrease in UPDRS Motor Exam (Part III) total score after identical doses of Parcopa and Sinemet: Onset times were similar: 43 minutes vs 47 minutes (Sinemet vs Parcopa, respectively)
Result source: NCT00139880
TR-012001
Developed by SNLD, Ltd.
NCT06212089 · Phase 2 · completed
The study randomly assigned 12 Japanese patients with Parkinson's disease to one nasal dose of TR-012001 or placebo, single-blind. Its registered primary outcomes were safety measures, so there is no efficacy comparison to call. The AAN 2025 abstract reports that all adverse drug reactions were mild, transient nasal reactions and that 8 of 9 treated patients reached peak plasma levodopa within 15 minutes. The study is very small and tested a single dose.
Conference abstract (AAN 2025); not peer reviewed and not posted on ClinicalTrials.gov.
Reported efficacy
Safety evaluation of TR-012001: Incidents of Treatment-Emergent Adverse Events (Day of administration of TR-012001/placebo (Day3) to the day of leaving the facility (Day4). If any adverse event(s) continue or occur on Day4, follow-up will be conducted until recovery or until the investigator decides no longer follow-up is necessary.); Safety evaluation of TR-012001: Incidents of physical findings (4 days and 3 nights); Safety evaluation of TR-012001: Vital sign (body temperature) (4 days and 3 nights); Safety evaluation of TR-012001: Vital sign (blood pressure) (4 days and 3 nights); Safety evaluation of TR-012001: Vital sign (pulse rate) (4 days and 3 nights); Safety evaluation of TR-012001: Columbia Suicide Severity Rating Scale (C-SSRS) (Day 1 and Day 4); Safety evaluation of TR-012001: Incidents of participants with laboratory abnormality (Day 1 and Day 4); Pharmacokinetics of TR-012001: Maximum plasma concentration (Cmax) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Time to reach maximum plasma concentration (Tmax) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Elimination half-life (t1/2) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Area under the plasma concentration-time curve (AUC0-inf) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Mean residence time (MRT) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Apparent whole body clearance (CL/f) (Pre-dose (baseline) and specified time points of post-dose); Pharmacokinetics of TR-012001: Volume of distribution (Vd/f ) (Pre-dose (baseline) and specified time points of post-dose): Single nasal dose in 12 patients (9 TR-012001, total levodopa 40 mg; 3 placebo): all adverse drug reactions were mild and transient nasal administration reactions, and all 12 patients completed. 8 of 9 TR-012001 patients reached peak plasma levodopa within 15 minutes of dosing. (not_applicable)
Result source: NCT06212089
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Parcopa | TR-012001 |
|---|---|---|
| OFF time, change | —Not posted · NCT00139880 | —Not reported |
| ON time without troublesome dyskinesia, change | —Not posted · NCT00139880 | —Not reported |
| UPDRS Part III, change | —Not posted · NCT00139880 | —Not reported |
| MDS-UPDRS Part II, change | —Not posted · NCT00139880 | —Not reported |
OFF time, change
- Parcopa
- —Not posted · NCT00139880
- TR-012001
- —Not reported
ON time without troublesome dyskinesia, change
- Parcopa
- —Not posted · NCT00139880
- TR-012001
- —Not reported
UPDRS Part III, change
- Parcopa
- —Not posted · NCT00139880
- TR-012001
- —Not reported
MDS-UPDRS Part II, change
- Parcopa
- —Not posted · NCT00139880
- TR-012001
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
TR-012001: no structured comparison results are available for Parkinson's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Parcopa: 2 of 4 rows · TR-012001: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Parcopa |
|---|---|
| Dropout rate | —a NCT00590122 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT00590122 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 0%a NCT00590122 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Parcopa
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Parcopa's landscape · TR-012001's landscape